Denver,Colorado- Callan JMB (NASDAQ:CJMB) took a meaningful step deeper into the federal medical countermeasure ecosystem with the announcement of a strategic teaming agreement with Biostax Corp d/b/a Attune Biotech Inc. The agreement positions Callan JMB as the independent third-party overseer of Attune’s manufacturing, quality, and deployment operations, with the parties targeting approximately $50–$75 million in combined revenue over the next five years, spanning both federal and commercial opportunities.
At the core of the partnership is speed and readiness. Callan JMB will provide end-to-end federal oversight, including manufacturing quality assurance, batch record review, BARDA compliance, FDA audit readiness, supply chain governance, and Strategic National Stockpile (SNS) deployment coordination. By leveraging its existing relationships and infrastructure across BARDA, the SNS, the Department of Defense, and the Department of Veterans Affairs, Callan JMB enables Attune to bypass the typical multi-year logistics ramp that new pharmaceutical programs face.
The collaboration builds on prior validation work. In late 2024, Attune and Callan JMB’s Coldchain Technology Services completed a surge-readiness simulation involving a 500,000-unit deployment across six SNS sites, meeting federal benchmarks for rapid activation while maintaining full regulatory compliance. The platform is now validated for 24-hour emergency deployment and nationwide distribution within 48 hours, underscoring its relevance for pandemic preparedness and emergency response.
Financially, the agreement outlines a profit-sharing structure that could translate into approximately $25–$45 million in potential revenue for Callan JMB over five years, depending on contract scope and execution. Strategically, it expands CJMB’s role from logistics provider to critical enabler of federal-grade pharmaceutical deployment.
Attune’s pipeline brings the medical substance behind the logistics. The company’s lead asset, Lodonal™ (JKB-122), is a first-in-class TLR4 antagonist under development across multiple immune-related indications, including Long COVID and metabolic liver disease, supported by multiple active FDA INDs and validated U.S.-based cGMP manufacturing. Additional assets include MENK-201, a peptide therapeutic with Phase 2 data in HIV and oncology, and Cytocide-100™, a broad-spectrum antimicrobial platform positioned for both OTC and emergency use.
Taken together, the agreement reflects a convergence of validated science and proven federal infrastructure. For Callan JMB, it reinforces a business model centered on readiness and execution at national scale. For Attune, it accelerates the path from clinical development to real-world deployment, where timing, compliance, and logistics can be just as critical as the therapies themselves.